Comparative evaluation of a newly developed 13-valent pneumococcal conjugate vaccine in a mouse model

References

• Gray BM, Dillon HC. Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis 1986; 5:201-7; PMID:3952010; http://dx.doi.org/10.1097/00006454-198603000-00009
   PubMedGoogle Scholar
• Austrian R, Gold J. Pneumococcal bacteremia with specific reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60:759–76; PMID:14156606; http://dx.doi.org/10.7326/0003-4819-60-5-759
   PubMed Web of Science ®Google Scholar
• Dagan R, Englehard D, Piccard E, Israeli Pediatric Bacteremia and Meningitis Group. Epidemiology of invasive childhood pneumococcal infections in Israel. JAMA 1992; 268:3328-32; PMID:1364814; http://dx.doi.org/10.1001/jama.1992.03490230058028
   PubMed Web of Science ®Google Scholar
• Obaro S, Adegbola R. The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol 2002; 51:98-104; PMID:11863272; http://dx.doi.org/10.1099/0022-1317-51-2-98
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826-31; PMID:8411526; http://dx.doi.org/10.1001/jama.1993.03510150060030
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of a polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453-60; PMID:1944423; http://dx.doi.org/10.1056/NEJM199111213252101
   PubMed Web of Science ®Google Scholar
• Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983; 148:131-7; PMID:6886479; http://dx.doi.org/10.1093/infdis/148.1.131
   PubMed Web of Science ®Google Scholar
• Lee CJ, Wang TR. Pneumococcal infection and immunization in children. Crit Rev Microbiol 1994; 20:1-12; http://dx.doi.org/10.3109/10408419409113544
   PubMed Web of Science ®Google Scholar
• Forrester HL, Jahningen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83:425-30; PMID:3661581; http://dx.doi.org/10.1016/0002-9343(87)90751-0
   PubMed Web of Science ®Google Scholar
• Anderson EL, Kennedy DJ, Geldmacher KM, Donnelly J, Mendelman PM. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996; 128:649-53; PMID:8627437; http://dx.doi.org/10.1016/S0022-3476(96)80130-2
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Austrian, K. Edwards, Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95; PMID:10749457; http://dx.doi.org/10.1097/00006454-200003000-00003
   PubMed Web of Science ®Google Scholar
• Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, Mendelman PM, Bohidar N, Yagupsky P. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis 1996; 174:1271-8; PMID:8940218; http://dx.doi.org/10.1093/infdis/174.6.1271
   PubMed Web of Science ®Google Scholar
• Dagan R, Givon-Lavi N, Zamir O, Sikuler-Cohen M, Guy L, Janco J, Yagupsky P, Fraser D. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002; 185:927-36; PMID:11920317; http://dx.doi.org/10.1086/339525
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Baxter R, Austrian R, Bracken L, Hansen J, Lewis E, Fireman B. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004; 23:485-9; PMID:15194827; http://dx.doi.org/10.1097/01.inf.0000129685.04847.94
   PubMed Web of Science ®Google Scholar
• Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili TD, Jackson D, et al; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348:1737-46; PMID:12724479; http://dx.doi.org/10.1056/NEJMoa022823
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Mason EO Jr, Wald ER, Schutze GE, Bradley JS, Tan TQ, Hoffman JA, Givner LB, Yogev R, Barson WJ. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 2004; 113:443-9; PMID:14993532; http://dx.doi.org/10.1542/peds.113.3.443
   PubMed Web of Science ®Google Scholar
• Byington CL, Samore MH, Stoddard GJ, Barlow S, Daly J, Korgenski K, Firth S, Glover D, Jensen J, Mason EO, et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005; 41:21-9; PMID:15937758; http://dx.doi.org/10.1086/430604
   PubMed Web of Science ®Google Scholar
• Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007; 44:1569-76; PMID:17516400; http://dx.doi.org/10.1086/518149
   PubMed Web of Science ®Google Scholar
• Gerdts V, Littel-van den Hurk Sv, Griebel PJ, Babiuk LA. Use of animal models in the development of human vaccines. Future Microbiol 2007; 2:667-75; PMID:18041907; http://dx.doi.org/10.2217/17460913.2.6.667
   PubMed Web of Science ®Google Scholar
• Alonso De Velasco E, Dekker BA, Verheul AF, Feldman RG, Verhoef J, Snippe H. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: Relationships with protection against Streptococcus pneumoniae infection in mice. J Infect Dis 1995; 172:562-5; PMID:7622906; http://dx.doi.org/10.1093/infdis/172.2.562
   PubMed Web of Science ®Google Scholar
• Musher DM, Johnson B Jr, Watson DA. Quantitative relationship between anticapsular antibody measured by enzyme linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4. Infect Immun 1990; 58:3871-6; PMID:2254015
   PubMed Web of Science ®Google Scholar
• Saeland E, Vidarsson G, Jonsdottir I. Pneumococcal pneumonia and bacteremia model in mice for the analysis of protective antibodies. Microb Pathog 2000; 29:81-91; PMID:10906263; http://dx.doi.org/10.1006/mpat.2000.0363
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Jonsdottir I, Jonsson S, Valdimarsson H. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae. J Infect Dis 1994; 170:592-9; PMID:8077716; http://dx.doi.org/10.1093/infdis/170.3.592
   PubMed Web of Science ®Google Scholar
• Fernsten P, Mason KW, Yu X, Tummolo D, Belanger KA, Tsao H, Zhu D, Cooper D, Hagen M, Jansen KU. 13-valent pneumococcal conjugate vaccine immune sera protects against pneumococcal serotype 1, 3, and 5 bacteremia in a neonatal rat challenge model. Hum Vaccin 2011; 7 Suppl:75-84; PMID:21266856; http://dx.doi.org/10.4161/hv.7.0.14566
   PubMed Web of Science ®Google Scholar
• Chiavolini D, Pozzi G, Ricci S. Animal models of Streptococcus pneumoniae disease. Clin Microbiol Rev 2008; 21:666-85; PMID:18854486; http://dx.doi.org/10.1128/CMR.00012-08
   PubMed Web of Science ®Google Scholar
• Steinhoff MC; The Pneumococcal Vaccine Animal Model Consensus Group. Animal models for protein pneumococcal vaccine evaluation: a summary. Vaccine 2007; 25:2465-70; PMID:17034908; http://dx.doi.org/10.1016/j.vaccine.2006.09.021
   PubMed Web of Science ®Google Scholar
• Plosker GL. 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents. Paediatr Drugs 2013; 15:403-23; PMID:24030738; http://dx.doi.org/10.1007/s40272-013-0047-z
   PubMed Web of Science ®Google Scholar
• McCool TL, Harding CV, Greenspan NS, Schreiber JR. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity. Infect Immun 1999; 67:4862-9; PMID:10456942
   PubMed Web of Science ®Google Scholar
• Concepcion NF, Frasch CE. Pneumococcal type 22F absorption improves the specificity of a pneumococcal polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72; PMID:11238206
   PubMedGoogle Scholar
• Tian H, Groner A, Boes M, Pirofski LA. Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice. Infect Immun 2007; 75:1643-50; PMID:17220309; http://dx.doi.org/10.1128/IAI.01371-06
   PubMed Web of Science ®Google Scholar
• Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW. Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 2001; 69:6718-24; PMID:11598043; http://dx.doi.org/10.1128/IAI.69.11.6718-6724.2001
   PubMed Web of Science ®Google Scholar
• Tian H, Weber S, Thorkildson P, Kozel TR, Pirofski LA. Efficacy of opsonic and nonopsonic serotype 3 pneumococcal capsular polysaccharide-specific monoclonal antibodies against intranasal challenge with Streptococcus pneumoniae in mice. Infect Immun 2009; 77:1502-13; PMID:19168739; http://dx.doi.org/10.1128/IAI.01075-08
   PubMed Web of Science ®Google Scholar
• Brito DA, Ramirez M, de Lencastre H. Serotyping Streptococcus pneumoniae by multiplex PCR. J Clin Microbiol 2003; 41:2378-84; PMID:12791852; http://dx.doi.org/10.1128/JCM.41.6.2378-2384.2003
   PubMed Web of Science ®Google Scholar
• Lee DG, Murakami Y, Andes DR, Craig WA. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 105 and 107 CFU injected into opposite thighs of neutropenic mice. Antimicrob Agents Chemother 2013; 57:1434-41; PMID:23295932; http://dx.doi.org/10.1128/AAC.00362-12
   PubMed Web of Science ®Google Scholar
• Shin HH, Han S, Yim DS, Lee DG, Park C, Kim SH, Kwon JC, Hong KW, Park SH, Choi SM, et al. Efficacy of vancomycin against Staphylococcus aureus according to inoculum size in a neutropenic mouse infection model. Infect Chemother 2011; 43:251-7; http://dx.doi.org/10.3947/ic.2011.43.3.251
   Google Scholar